Skip to main content
PMC home page
Gut logoLink to Gut
. 1993 Jun;34(6):794–798. doi: 10.1136/gut.34.6.794

Effects of serotonin on rat ileocolonic transit and fluid transfer in vivo: possible mechanisms of action.

L Oosterbosch 1, M von der Ohe 1, M A Valdovinos 1, L J Kost 1, S F Phillips 1, M Camilleri 1
PMCID: PMC1374264  PMID: 8100206

Abstract

The aim was to investigate the action of serotonin (5HT) on function of the ileocolonic junction (ICJ) in vivo. In anaesthetised rats, models were developed to study the effects of intra-aortic (ia) serotonin on ileocolonic and colonic transit, and the effects on transit of a number of 5HT receptor antagonists. In the first series of experiments, a bolus of saline labelled with 99mTc DTPA was instilled 20 cm proximal to the ICJ and transit was assessed three hours later by the geometric centre of the spread of isotope. In the second series, similar techniques were used on the postcaecal colon and transit assessed two hours later. In the third series of experiments, the effects of ia 5HT on ileal net fluid flux was evaluated by standard perfusion experiments with 14C polyethylene glycol (PEG) 4000 as a non-absorbable marker in rat plasma-like electrolyte solution. Compared with ia saline, 5HT accelerated ICJ transit significantly (p < 0.05). This acceleration was comparable with the effect of ia bethanechol. The effects of 5HT on ICJ transit were inhibited by the intraperitoneal (ip) infusion of atropine, the 5HT receptor antagonists, methysergide, ketanserin, zacopride, and the 5HT4 agonist, SC53116. Methysergide, zacopride, and SC53116 given with ia 5HT slowed ICJ transit to rates below those of ia saline alone. When these same agents were given together with ia saline, the ICJ transit was not significantly altered. Serotonin, at the dose that accelerated ICJ transit, did not significantly alter colonic transit or ileal fluid transport. In conclusion, 5HT is a potent pharmacological stimulant of transit across the rat ICJ in vivo; the action of 5HT is mediated partly through muscarinic neurones and several 5HT receptor subtypes.

Full text

PDF
794

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. V., Coupe M. O., Morris J. A., Hodgson H. J., Bloom S. R. Remission of symptoms in carcinoid syndrome with a new 5-hydroxytryptamine M receptor antagonist. Br Med J (Clin Res Ed) 1987 May 2;294(6580):1129–1129. doi: 10.1136/bmj.294.6580.1129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BULBRING E., LIN R. C. The effect of intraluminal application of 5-hydroxytryptamine and 5-hydroxytryptophan on peristalsis; the local production of 5-HT and its release in relation to intraluminal pressure and propulsive activity. J Physiol. 1958 Mar 11;140(3):381–407. [PMC free article] [PubMed] [Google Scholar]
  3. Boeckxstaens G. E., Pelckmans P. A., Rampart M., Bogers J. J., Verbeuren T. J., Herman A. G., Van Maercke Y. M. Pharmacological characterization of 5-hydroxytryptamine receptors in the canine terminal ileum and ileocolonic junction. J Pharmacol Exp Ther. 1990 Aug;254(2):652–658. [PubMed] [Google Scholar]
  4. Bom A. H., Duncker D. J., Saxena P. R., Verdouw P. D. 5-Hydroxytryptamine-induced tachycardia in the pig: possible involvement of a new type of 5-hydroxytryptamine receptor. Br J Pharmacol. 1988 Mar;93(3):663–671. doi: 10.1111/j.1476-5381.1988.tb10324.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bradley P. B., Engel G., Feniuk W., Fozard J. R., Humphrey P. P., Middlemiss D. N., Mylecharane E. J., Richardson B. P., Saxena P. R. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology. 1986 Jun;25(6):563–576. doi: 10.1016/0028-3908(86)90207-8. [DOI] [PubMed] [Google Scholar]
  6. Buchheit K. H., Engel G., Mutschler E., Richardson B. Study of the contractile effect of 5-hydroxytryptamine (5-HT) in the isolated longitudinal muscle strip from guinea-pig ileum. Evidence for two distinct release mechanisms. Naunyn Schmiedebergs Arch Pharmacol. 1985 Mar;329(1):36–41. doi: 10.1007/BF00695189. [DOI] [PubMed] [Google Scholar]
  7. Costa M., Furness J. B. The sites of action of 5-hydroxytryptamine in nerve-muscle preparations from the guinea-pig small intestine and colon. Br J Pharmacol. 1979 Feb;65(2):237–248. doi: 10.1111/j.1476-5381.1979.tb07824.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Costall B., Naylor R. J. 5-Hydroxytryptamine: new receptors and novel drugs for gastrointestinal motor disorders. Scand J Gastroenterol. 1990 Aug;25(8):769–787. doi: 10.3109/00365529008999215. [DOI] [PubMed] [Google Scholar]
  9. Craig D. A., Clarke D. E. Pharmacological characterization of a neuronal receptor for 5-hydroxytryptamine in guinea pig ileum with properties similar to the 5-hydroxytryptamine receptor. J Pharmacol Exp Ther. 1990 Mar;252(3):1378–1386. [PubMed] [Google Scholar]
  10. Dumuis A., Bouhelal R., Sebben M., Cory R., Bockaert J. A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol Pharmacol. 1988 Dec;34(6):880–887. [PubMed] [Google Scholar]
  11. Elswood C. J., Bunce K. T., Humphrey P. P. Identification of putative 5-HT4 receptors in guinea-pig ascending colon. Eur J Pharmacol. 1991 Apr 17;196(2):149–155. doi: 10.1016/0014-2999(91)90421-l. [DOI] [PubMed] [Google Scholar]
  12. Emson P. C., Gilbert R. F., Martensson H., Nobin A. Elevated concentrations of substance P and 5-HT in plasma in patients with carcinoid tumors. Cancer. 1984 Aug 15;54(4):715–718. doi: 10.1002/1097-0142(1984)54:4<715::aid-cncr2820540420>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  13. Feldman J. M. Carcinoid tumors and syndrome. Semin Oncol. 1987 Sep;14(3):237–246. [PubMed] [Google Scholar]
  14. Feldman J. M., Plonk J. W. Gastrointestinal and metabolic function in patients with the carcinoid syndrome. Am J Med Sci. 1977 Jan-Feb;273(1):43–54. doi: 10.1097/00000441-197701000-00004. [DOI] [PubMed] [Google Scholar]
  15. Frieling T., Cooke H. J., Wood J. D. Serotonin receptors on submucous neurons in guinea pig colon. Am J Physiol. 1991 Dec;261(6 Pt 1):G1017–G1023. doi: 10.1152/ajpgi.1991.261.6.G1017. [DOI] [PubMed] [Google Scholar]
  16. Gershon M. D., Tamir H. Release of endogenous 5-hydroxytryptamine from resting and stimulated enteric neurons. Neuroscience. 1981;6(11):2277–2286. doi: 10.1016/0306-4522(81)90017-8. [DOI] [PubMed] [Google Scholar]
  17. Goldberg M., Hanani M., Nissan S. Effects of serotonin on the internal anal sphincter: in vivo manometric study in rats. Gut. 1986 Jan;27(1):49–54. doi: 10.1136/gut.27.1.49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gustafsen J., Lendorf A., Raskov H., Boesby S. Ketanserin versus placebo in carcinoid syndrome. A clinical controlled trial. Scand J Gastroenterol. 1986 Sep;21(7):816–818. doi: 10.3109/00365528609011123. [DOI] [PubMed] [Google Scholar]
  19. HENDRIX T. R., ATKINSON M., CLIFTON J. A., INGELFINGER F. J. The effect of 5-hydroxytryptamine on intestinal motor function in man. Am J Med. 1957 Dec;23(6):886–893. doi: 10.1016/0002-9343(57)90298-x. [DOI] [PubMed] [Google Scholar]
  20. Jacoby H. I., Bonfilio A. C., Raffa R. B. Central and peripheral administration of serotonin produces opposite effects on mouse colonic propulsive motility. Neurosci Lett. 1991 Jan 14;122(1):122–126. doi: 10.1016/0304-3940(91)90208-b. [DOI] [PubMed] [Google Scholar]
  21. KOSTERLITZ H. W., ROBINSON J. A. Inhibition of the peristaltic reflex of the isolated guinea-pig ileum. J Physiol. 1957 Apr 30;136(2):249–262. doi: 10.1113/jphysiol.1957.sp005757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. KOWLESSAR O. D., LAW D. H., SLEISENGER M. H. Malabsorption syndrome associated with metastatic carcinoid tumor. Am J Med. 1959 Oct;27:673–677. doi: 10.1016/0002-9343(59)90051-8. [DOI] [PubMed] [Google Scholar]
  23. Kaumann A. J., Sanders L., Brown A. M., Murray K. J., Brown M. J. A 5-hydroxytryptamine receptor in human atrium. Br J Pharmacol. 1990 Aug;100(4):879–885. doi: 10.1111/j.1476-5381.1990.tb14108.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lidberg P., Dahlström A., Ahlman H. Is 5-HT a mediator in the motor control of the feline pylorus? Scand J Gastroenterol. 1984 May;19(3):321–328. [PubMed] [Google Scholar]
  25. Miller M. S., Galligan J. J., Burks T. F. Accurate measurement of intestinal transit in the rat. J Pharmacol Methods. 1981 Nov;6(3):211–217. doi: 10.1016/0160-5402(81)90110-8. [DOI] [PubMed] [Google Scholar]
  26. Ng W. W., Jing J., Hyman P. E., Snape W. J., Jr Effect of 5-hydroxytryptamine and its antagonists on colonic smooth muscle of the rabbit. Dig Dis Sci. 1991 Feb;36(2):168–173. doi: 10.1007/BF01300751. [DOI] [PubMed] [Google Scholar]
  27. Oberg K., Theodorsson-Norheim E., Norheim I. Motilin in plasma and tumor tissues from patients with the carcinoid syndrome. Possible involvement in the increased frequency of bowel movements. Scand J Gastroenterol. 1987 Nov;22(9):1041–1048. doi: 10.3109/00365528708991954. [DOI] [PubMed] [Google Scholar]
  28. Ouyang A., Cohen S. Multiple 5-hydroxytryptamine receptors on feline ileum and ileocecal sphincter. Am J Physiol. 1983 Apr;244(4):G426–G434. doi: 10.1152/ajpgi.1983.244.4.G426. [DOI] [PubMed] [Google Scholar]
  29. PEART W. S., ROBERTSON J. I. The effect of a serotonin antagonist (UML 491) in carcinoid disease. Lancet. 1961 Nov 25;2(7213):1172–1174. doi: 10.1016/s0140-6736(61)90846-7. [DOI] [PubMed] [Google Scholar]
  30. Phillips S. F., Quigley E. M., Kumar D., Kamath P. S. Motility of the ileocolonic junction. Gut. 1988 Mar;29(3):390–406. doi: 10.1136/gut.29.3.390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Rubin M. R., Cardwell B. A., Ouyang A., Snape W. J., Jr, Cohen S. Effect of bethanechol or vagal nerve stimulation on ileocecal sphincter pressure in the cat. Gastroenterology. 1981 May;80(5 Pt 1):974–979. [PubMed] [Google Scholar]
  32. Ruytjens I., Thomforde G. M., Camilleri M., Chapman N. J. Effect of chemical sympathectomy on scintigraphic gastric and small bowel transit in the rat. J Auton Nerv Syst. 1992 Jun 15;39(2):111–117. doi: 10.1016/0165-1838(92)90051-h. [DOI] [PubMed] [Google Scholar]
  33. SAUER W. G. Carcinoidosis and the effect of serotonin on the gastrointestinal tract. Am J Dig Dis. 1961 Sep;6:906–913. doi: 10.1007/BF02231087. [DOI] [PubMed] [Google Scholar]
  34. Satterlee W. G., Serpick A., Bianchine J. R. The carcinoid syndrome: chronic treatment with para-chlorophenylalanine. Ann Intern Med. 1970 Jun;72(6):919–921. doi: 10.7326/0003-4819-72-6-919. [DOI] [PubMed] [Google Scholar]
  35. Uguru M. O., Bamgbose S. O. Mechanisms of the relaxations induced by 5-hydroxytryptamine on the rat isolated caecum. J Pharm Pharmacol. 1986 Feb;38(2):140–143. doi: 10.1111/j.2042-7158.1986.tb04530.x. [DOI] [PubMed] [Google Scholar]
  36. Villalón C. M., den Boer M. O., Heiligers J. P., Saxena P. R. Mediation of 5-hydroxytryptamine-induced tachycardia in the pig by the putative 5-HT4 receptor. Br J Pharmacol. 1990 Aug;100(4):665–667. doi: 10.1111/j.1476-5381.1990.tb14073.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES